Iradimed Corp key statistics and ratios

In fiscal 2025, Iradimed Corp had return on equity of 24.8%, an operating margin of 31.2%, debt equal to 0.0% of equity and a current ratio of 7.98. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Iradimed Corp: financial ratios, annual
Fiscal year	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Gross margin	74.8%	78.3%	81.5%	81.1%	75.9%	76.3%	77.1%	74.3%	76.6%	77.4%	76.5%	76.9%	76.7%	75.5%
Operating margin	24.6%	19.6%	36.4%	33.6%	5.6%	19.7%	22.5%	−2.4%	23.5%	29.3%	30.6%	30.0%	31.2%	32.3%
Net margin	17.1%	13.1%	23.8%	22.2%	2.2%	20.7%	25.0%	4.3%	22.3%	24.1%	26.2%	26.3%	26.8%	26.8%
Free-cash-flow margin	11.6%	12.8%	23.3%	26.5%	11.4%	23.5%	25.6%	16.9%	25.8%	17.3%	9.2%	24.1%	20.5%	29.3%
Return on equity	35.7%	15.6%	28.5%	22.6%	1.5%	16.8%	19.8%	2.3%	14.0%	17.6%	23.7%	24.3%	24.8%	23.9%
Return on assets	27.7%	13.5%	25.7%	19.9%	1.3%	14.4%	16.7%	2.0%	12.1%	15.2%	19.4%	20.2%	21.7%	20.9%
Asset turnover	1.62	1.03	1.08	0.90	0.61	0.70	0.67	0.46	0.54	0.63	0.74	0.77	0.81	0.78
Current ratio	4.40	9.74	11.76	9.25	8.61	9.50	10.06	12.96	11.18	9.06	4.65	8.84	7.98	8.99
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Effective tax rate	30.4%	32.0%	35.3%	34.1%	64.2%	−1.7%	−6.5%	—	5.2%	20.7%	20.9%	20.8%	20.7%	22.9%
R&D as % of revenue	8.9%	6.8%	5.6%	4.1%	7.5%	5.0%	3.7%	6.0%	4.6%	4.3%	4.4%	3.9%	3.5%	3.7%
Capital spending as % of revenue	1.4%	3.7%	0.9%	2.4%	3.4%	0.8%	1.0%	1.4%	1.2%	1.5%	11.3%	10.9%	9.3%	1.1%
Free cash flow ÷ net income	67.7%	97.6%	97.6%	119.6%	528.3%	113.4%	102.4%	392.6%	115.6%	71.9%	35.0%	91.6%	76.4%	109.0%
Dividends ÷ net income	—	—	—	—	—	—	—	—	—	97.9%	76.9%	71.1%	66.9%	67.6%
Dividends and buybacks ÷ free cash flow	—	—	—	115.6%	68.9%	—	—	—	—	136.2%	219.5%	77.6%	87.5%	62.1%

US$ thousands unless shown otherwise. Fiscal quarters.

Iradimed Corp: financial ratios, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Gross margin	76.1%	76.1%	78.2%	77.8%	75.1%	76.5%	74.1%	76.3%
Operating margin	29.9%	27.8%	33.3%	32.2%	31.3%	32.9%	31.2%	33.6%
Net margin	26.5%	24.0%	28.3%	26.3%	28.4%	26.5%	25.5%	26.9%
Free-cash-flow margin	16.5%	3.0%	25.0%	27.6%	24.8%	35.9%	28.1%	28.4%
Current ratio	8.84	8.87	8.78	6.64	7.98	7.13	9.46	8.99
R&D as % of revenue	2.9%	3.2%	4.3%	3.2%	3.5%	4.3%	3.2%	3.6%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · September 30, 2026

What it owns · $121m

Short-term assets $93mLonger-term assets $28m

What it owes, and who funded it · $121m

Short-term liabilities $10mLonger-term liabilities $4mShareholders' equity $106m

Short-term assets cover short-term liabilities $93m of assets due within a year against $10m of liabilities due within a year.
Short-term assets cover long-term liabilities $93m short-term assets against $4m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Iradimed Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

81 /100

Strong moat

How hard Iradimed's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 17 / 20

Cash operating profit has been a median 13.2% of total assets over 10 years.
Pricing power 20 / 20

Gross margin has been a median 76.4%, moving by 1.1 percentage points (standard deviation) across 10 years.
Durability 10 / 20

Operating margin has been a median 25.8%; its worst year was 2.4%.
Cash conversion 20 / 20

Free cash flow was positive in 10 of 10 years, at a median 19.6% of revenue.
Discipline 14 / 20

The diluted share count rose 2.0% over five years; stock-based pay has been a median 3.6% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: IRMD vs LUNG DCTH vs IRMD IRMD vs SGHT

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Iradimed Corp's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Iradimed Corp.